Opioid Approval Delay? Class REMS Poses Legal Questions For Pending Drugs, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of New Drugs Director John Jenkins explains the agency’s options in approving pending potent opioids in lieu of a class-wide REMS.
You may also be interested in...
FDA Will Require Class-Wide REMS For Opioids; “Massive” Program Compared To Past Efforts
Class-wide REMS will encompass 24 marketed products from 16 different manufacturers; focus on extended-release products.
FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.
Fentora Expansion Awaits REMS Evaluation
“Complete response” letter calls for Cephalon to “demonstrate” that risk management works before Fentora can add new indication.